(COG AAML1522/CC-5013-AML-002) A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 to = 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
Description: 
To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or Refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a complete response (CR) or complete remission with incomplete blood count recovery (CRi) within the first 4 cycles of treatment.
Study Number: 

PH 278315

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02538965

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.